Skip to content

Real world evidence of positive inotropic drugs in the treatment of ACS complicated with acute heart failure

A cohort study on the efficacy and prognostic factors of multicenter positive inotropic drugs in the treatment of ACS complicated with acute heart failure

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063775
Enrollment
Unknown
Registered
2022-09-16
Start date
2022-09-15
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

None listed

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The age is 18-85 years old, regardless of gender; 2. The patients with ACS with acute heart failure who have been diagnosed clearly meet the following requirements at admission: (1) Chest tightness, chest pain, shortness of breath, fatigue, palpitations or upright breathing or nocturnal paroxysmal dyspnea at rest or during activities; (2) ECG showed myocardial ischemia; (3) NT proBNP >= 125 ng/L or BNP >= 35 ng/L; (4) Echocardiography: abnormal cardiac structure and/or function; 3. Receive positive inotropic drug injection to treat current acute HF attack; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Major surgery, including implantable devices (such as ICDs and CRTs), or major nervous system events, including cerebrovascular events, occurs within 1 month; 2. Patients with hypertrophic obstructive cardiomyopathy; 3. Patients with severe liver and kidney (creatinine clearance rate < 30 ml/min) functional damage, patients with severe hypotension and tachycardia, and patients with a history of torsade de pointes ventricular tachycardia; 4. Poor compliance, unable to cooperate in completing the test; 5. Other conditions that doctors think are not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
brain natriuretic peptide, BNP;

Countries

China

Contacts

Public ContactHaotao Yuan

Shandong Provincial Hospital

doctoryuanht@126.com+86 13688638072

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026